HOME
CAREER NETWORK
NEWS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
BIOPHARM INSIGHT
ABOUT US
NEWSLETTERS FREE Newsletters Archive My eNewsletters NEWS News by Subject News by Date Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Today's Hot Jobs Most Recent Jobs Search Jobs Post Resume Career Resources For Employers COMMUNITY Login Become a Member FAQ PROFILES Company Profiles INDUSTRY EVENTS Clinical RESOURCES Real Estate New Business Opportunities
EurekAlert! -- Pancreatic cancer is a devastating disease with poor prognosis. This warrants the development of novel therapies including gene therapy. However, clinical studies have demonstrated poor efficacy of adenoviral gene therapy because of the absence of adenoviral binding sites on pancreatic cancer cells such as the coxsackie and adenovirus receptor (CAR). Circumventing CAR-mediated entry therefore seems a promising option to improve adenoviral entry into pancreatic cancer cells and to enhance the efficacy of adenoviral vectors.